Novartis After the Pullback: A Measured Long-Term Buy with a Defined Risk Plan
Novartis (NVS) has pulled back into the $150 area after a broader pharma rotation and some pipeline noise. With a market cap near $309B, $9.69B in free cash flow and low leverage, the company can fund R&D and M&A while paying a meaningful annual dividend. Positive remibrutinib data and a $7.8B Abogen RNA deal are near-term catalysts that justify a …